Zerboni, L., Sen, N., Oliver, S. L. & Arvin, A. M. Molecular mechanisms of varicella zoster virus pathogenesis. Nat. Rev. Microbiol 12, 197–210 (2014).
Article PubMed PubMed Central CAS Google Scholar
Levin, M. J. et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197, 825–835 (2008).
Article PubMed PubMed Central CAS Google Scholar
Arvin, A. Aging, immunity, and the varicella-zoster virus. N. Engl. J. Med. 352, 2266–2267 (2005).
Article PubMed CAS Google Scholar
Weinberg, A. et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200, 1068–1077 (2009).
Article PubMed PubMed Central CAS Google Scholar
Arvin, A. M. Humoral and cellular immunity to varicella-zoster virus: an overview. J. Infect. Dis. 197, S58–S60 (2008).
Article PubMed CAS Google Scholar
Asada, H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine 37, 6776–6781 (2019).
Article PubMed CAS Google Scholar
Gilbert, P. B. et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J. Infect. Dis. 210, 1573–1581 (2014).
Article PubMed PubMed Central CAS Google Scholar
Kimura, H. et al. Comparison of quantitations of viral load in varicella and zoster. J. Clin. Microbiol 38, 2447–2449 (2000).
Article PubMed PubMed Central CAS Google Scholar
Satyaprakash, A. K. et al. Viremia in acute herpes zoster. J. Infect. Dis. 200, 26–32 (2009).
Rodriguez, J. E., Moninger, T. & Grose, C. Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 196, 840–844 (1993).
Article PubMed CAS Google Scholar
Etzioni, A. et al. Fatal varicella associated with selective natural killer cell deficiency. J. Pediatr. 146, 423–425 (2005).
Levy, O. et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188, 948–953 (2003).
Levin, M. J., Duchon, J. M., Swamy, G. K. & Gershon, A. A. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 14, e0217749 (2019).
Article PubMed PubMed Central CAS Google Scholar
Zaia, J. A. et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J. Infect. Dis. 147, 737–743 (1983).
Article PubMed CAS Google Scholar
Tilden, A. B. et al. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J. Immunol. 136, 4243–4248 (1986).
Babbage, J., Sigfusson, A. & Souhami, R. L. Antibody-dependent cell-mediated cytotoxicity to Varicella zoster. Clin. Exp. Immunol. 58, 217–222 (1984).
PubMed PubMed Central CAS Google Scholar
Ito, M., Ihara, T., Grose, C. & Starr, S. Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J. Virol. 54, 98–103 (1985).
Article PubMed PubMed Central CAS Google Scholar
Gershon, A. A. & Steinberg, S. P. Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody. Infect. Immun. 33, 507–511 (1981).
Article PubMed PubMed Central CAS Google Scholar
Levin, M. J. & Weinberg, A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin. Infect. Dis. 70, 1509–1515 (2020).
Weinberg, A. et al. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J. Infect. Dis. 218, S81–S87 (2018).
Damelang, T., Rogerson, S. J., Kent, S. J. & Chung, A. W. Role of IgG3 in Infectious Diseases. Trends Immunol. 40, 197–211 (2019).
Article PubMed CAS Google Scholar
Asano, Y. et al. Immunoglobulin Subclass Antibodies to Varicefla-Zoster Virus. Pediatrics 80, 933–936 (1987).
Article PubMed CAS Google Scholar
Echevarr et al. Subclass Distribution of the Serum and Intrathecal IgG Antibody Response in Varicella-Zoster Virus Infections. J. Infect. Dis. 162, 621–626 (1990).
Coignard, J. et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat. Commun. 12, 1078 (2021).
Article PubMed PubMed Central CAS Google Scholar
Richardson, S. I. et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 15, e1008064 (2019).
Article PubMed PubMed Central CAS Google Scholar
Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465–470 (2021).
Article PubMed PubMed Central CAS Google Scholar
Zhong, W. et al. Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans. Open Forum Infect. Dis. 3, ofw102 (2016).
Article PubMed PubMed Central Google Scholar
He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931–11936 (2016).
Article PubMed PubMed Central CAS Google Scholar
Sun, P. et al. NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients. J. Immunol. Methods 441, 24–30 (2017).
Article PubMed CAS Google Scholar
Ihara, T. et al. Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr. Jpn 33, 43–49 (1991).
Article PubMed CAS Google Scholar
Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521–11532 (2012).
Article PubMed PubMed Central CAS Google Scholar
Jegaskanda, S. et al. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. J. Infect. Dis. 214, 945–952 (2016).
Article PubMed PubMed Central CAS Google Scholar
Jegaskanda, S., Reading, P. C. & Kent, S. J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193, 469–475 (2014).
Article PubMed CAS Google Scholar
Cunningham, A. L. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N. Engl. J. Med. 375, 1019–1032 (2016).
Article PubMed CAS Google Scholar
Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087–2096 (2015).
Levin, M. J. et al. Th1 memory differentiates recombinant from live herpes zoster vaccines. J. Clin. Invest 128, 4429–4440 (2018).
Article PubMed PubMed Central Google Scholar
Schmid, D. S. et al. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. J. Virol. 95, e00240–00221 (2021).
留言 (0)